<p>根据 Donoghue Forlines LLC 最近向证券交易委员会（SEC）提交的文件，该公司在第一季度购买了强生（Johnson &amp; Johnson）（纽约证券交易所代码：JNJ - 免费报告）的新头寸。该公司购买了 8,934 股该公司的股票，价值约为 1,482,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>3 个强劲收益支撑的大型分红股票</li>
</ul>
<p>其他几家机构投资者也增加或减少了对该公司的持股。Highline Wealth Partners LLC 在第一季度将其在强生的股份增加了 51.8%。Highline Wealth Partners LLC 目前拥有 252 股该公司的股票，价值 42,000 美元，此前在上个季度又购买了 86 股。von Borstel &amp; Associates Inc.在第一季度购买了强生的新头寸，价值 49,000 美元。Capital A Wealth Management LLC 在第四季度购买了强生的新头寸，价值 50,000 美元。Harvest Fund Management Co. Ltd 在第一季度购买了强生的新头寸，价值 52,000 美元。最后，Accredited Wealth Management LLC 在第四季度购买了强生的新头寸，价值 58,000 美元。目前 69.55% 的股票由机构投资者持有。</p>
<h2>强生股价上涨 1.1%</h2>
<p>强生的股票在周五开盘价为 173.40 美元。强生的 1 年最低价为 140.68 美元，1 年最高价为 173.96 美元。该公司的 50 日移动平均线为 159.26 美元，200 日移动平均线为 157.44 美元。该公司的市值为 4,176.1 亿美元，市盈率为 18.55，PEG 比率为 2.18，贝塔系数为 0.41。该公司的债务与股本比率为 0.50，流动比率为 1.01，速动比率为 0.76。</p>
<ul>
<li>担心反弹消退？考虑这 3 只分红股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 7 月 16 日（星期三）公布了季度财报。该公司报告每股收益为 2.77 美元，超出分析师一致预期的 2.68 美元，超出 0.09 美元。强生的净利润率为 25.00%，股本回报率为 32.49%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。去年同期，该公司的每股收益为 2.82 美元。该公司的季度收入同比增长 5.8%。研究分析师平均预计强生在当前年度的每股收益为 10.58 美元。</p>
<h2>强生宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的登记投资者将获得每股 1.30 美元的分红。除息日为 8 月 26 日（星期二）。这代表着年化分红为 5.20 美元，收益率为 3.0%。强生的分红支付比率（DPR）目前为 55.61%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>4 只主要股票上调 2025 年指引，分析师目标上升</li>
</ul>
<p>几位股票分析师最近对该股发表了看法。美国银行在 7 月 17 日的研究报告中将强生的目标价从 161.00 美元上调至 175.00 美元，并给予该公司 “中性” 评级。瑞银集团在 7 月 17 日的研究报告中将强生的目标价从 180.00 美元上调至 190.00 美元，并给予该公司 “买入” 评级。巴克莱在 7 月 17 日的研究报告中将强生的目标价从 165.00 美元上调至 176.00 美元，并给予该公司 “等权重” 评级。派珀·桑德勒在 7 月 17 日的研究报告中重申了对强生的 “增持” 评级。最后，Leerink Partnrs 在 5 月 13 日的研究报告中将强生的评级从 “强力买入” 下调至 “持有”。九位研究分析师对该股给予了持有评级，十位给予了买入评级，两位给予了强力买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 174.50 美元。</p>
<p><strong>查看我们关于强生的最新报告</strong></p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过强生</li>
<li>8 月值得关注的 3 只最佳零售股票</li>
<li>Airbnb 超出收益预期，但增长故事正在失去高度</li>
<li>如何使用 MarketBeat 分红计算器</li>
<li>Netflix 多头与空头：谁将在这次回调中获胜？</li>
<li>宝洁（Procter &amp; Gamble）在不稳定的指引后回调</li>
<li>Viasat：为什么一大笔现金让空头们四处逃窜</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在强生吗？</h2>
<p>在考虑强生之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Donoghue Forlines LLC 在第一季度对强生（NYSE:JNJ）进行了约 148 万美元的新投资，购买了 8,934 股。其他机构投资者也调整了他们在该公司的持股。强生的股票目前交易价格为 173.40 美元，市值为 4176.1 亿美元。该公司最近报告每股收益为 2.77 美元，超出预期，并宣布季度股息为每股 1.30 美元。分析师对该股票的评级各不相同，普遍目标价为 174.50 美元</p>

<p>Donoghue Forlines LLC purchased a new position in Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 8,934 shares of the company's stock, valued at approximately $1,482,000.</p>
<div class="lb-trans"><p>根据 Donoghue Forlines LLC 最近向证券交易委员会（SEC）提交的文件，该公司在第一季度购买了强生（Johnson &amp; Johnson）（纽约证券交易所代码：JNJ - 免费报告）的新头寸。该公司购买了 8,934 股该公司的股票，价值约为 1,482,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 个强劲收益支撑的大型分红股票</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in the business. Highline Wealth Partners LLC increased its stake in shares of Johnson &amp; Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. von Borstel &amp; Associates Inc. purchased a new position in Johnson &amp; Johnson during the first quarter valued at $49,000. Capital A Wealth Management LLC purchased a new position in Johnson &amp; Johnson during the fourth quarter valued at $50,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson &amp; Johnson during the first quarter valued at $52,000. Finally, Accredited Wealth Management LLC purchased a new position in Johnson &amp; Johnson during the fourth quarter valued at $58,000. 69.55% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者也增加或减少了对该公司的持股。Highline Wealth Partners LLC 在第一季度将其在强生的股份增加了 51.8%。Highline Wealth Partners LLC 目前拥有 252 股该公司的股票，价值 42,000 美元，此前在上个季度又购买了 86 股。von Borstel &amp; Associates Inc.在第一季度购买了强生的新头寸，价值 49,000 美元。Capital A Wealth Management LLC 在第四季度购买了强生的新头寸，价值 50,000 美元。Harvest Fund Management Co. Ltd 在第一季度购买了强生的新头寸，价值 52,000 美元。最后，Accredited Wealth Management LLC 在第四季度购买了强生的新头寸，价值 58,000 美元。目前 69.55% 的股票由机构投资者持有。</p>
</div><h2>Johnson &amp; Johnson Trading Up 1.1%</h2>
<div class="lb-trans"><h2>强生股价上涨 1.1%</h2>
</div><p>Shares of JNJ opened at $173.40 on Friday. Johnson &amp; Johnson has a 1-year low of $140.68 and a 1-year high of $173.96. The company has a 50-day moving average of $159.26 and a 200 day moving average of $157.44. The firm has a market capitalization of $417.61 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 2.18 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.</p>
<div class="lb-trans"><p>强生的股票在周五开盘价为 173.40 美元。强生的 1 年最低价为 140.68 美元，1 年最高价为 173.96 美元。该公司的 50 日移动平均线为 159.26 美元，200 日移动平均线为 157.44 美元。该公司的市值为 4,176.1 亿美元，市盈率为 18.55，PEG 比率为 2.18，贝塔系数为 0.41。该公司的债务与股本比率为 0.50，流动比率为 1.01，速动比率为 0.76。</p>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>担心反弹消退？考虑这 3 只分红股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. On average, research analysts expect that Johnson &amp; Johnson will post 10.58 EPS for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 7 月 16 日（星期三）公布了季度财报。该公司报告每股收益为 2.77 美元，超出分析师一致预期的 2.68 美元，超出 0.09 美元。强生的净利润率为 25.00%，股本回报率为 32.49%。该公司在本季度的收入为 237.4 亿美元，而分析师预期为 228.5 亿美元。去年同期，该公司的每股收益为 2.82 美元。该公司的季度收入同比增长 5.8%。研究分析师平均预计强生在当前年度的每股收益为 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 55.61%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 9 月 9 日（星期二）支付。8 月 26 日（星期二）的登记投资者将获得每股 1.30 美元的分红。除息日为 8 月 26 日（星期二）。这代表着年化分红为 5.20 美元，收益率为 3.0%。强生的分红支付比率（DPR）目前为 55.61%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只主要股票上调 2025 年指引，分析师目标上升</li>
</ul>
</div><p>Several equities analysts recently weighed in on the stock. Bank of America raised their target price on shares of Johnson &amp; Johnson from $161.00 to $175.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, July 17th. UBS Group raised their target price on shares of Johnson &amp; Johnson from $180.00 to $190.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, July 17th. Barclays raised their target price on shares of Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Piper Sandler reaffirmed an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Finally, Leerink Partnrs cut shares of Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $174.50.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股发表了看法。美国银行在 7 月 17 日的研究报告中将强生的目标价从 161.00 美元上调至 175.00 美元，并给予该公司 “中性” 评级。瑞银集团在 7 月 17 日的研究报告中将强生的目标价从 180.00 美元上调至 190.00 美元，并给予该公司 “买入” 评级。巴克莱在 7 月 17 日的研究报告中将强生的目标价从 165.00 美元上调至 176.00 美元，并给予该公司 “等权重” 评级。派珀·桑德勒在 7 月 17 日的研究报告中重申了对强生的 “增持” 评级。最后，Leerink Partnrs 在 5 月 13 日的研究报告中将强生的评级从 “强力买入” 下调至 “持有”。九位研究分析师对该股给予了持有评级，十位给予了买入评级，两位给予了强力买入评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 174.50 美元。</p>
</div><p><strong>View Our Latest Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>查看我们关于强生的最新报告</strong></p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>The 3 Best Retail Stocks to Shop for in August</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
<li>Procter &amp; Gamble NYSE: PG Pulls Back After Shaky Guidance</li>
<li>Viasat: Why a Wall of Cash Has Shorts Running for Cover</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过强生</li>
<li>8 月值得关注的 3 只最佳零售股票</li>
<li>Airbnb 超出收益预期，但增长故事正在失去高度</li>
<li>如何使用 MarketBeat 分红计算器</li>
<li>Netflix 多头与空头：谁将在这次回调中获胜？</li>
<li>宝洁（Procter &amp; Gamble）在不稳定的指引后回调</li>
<li>Viasat：为什么一大笔现金让空头们四处逃窜</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Donoghue Forlines LLC 对强生公司（NYSE: JNJ）进行了新的 148 万美元投资